Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBLB | Q13191 | 20/20 | 0.62 |
| ▸ | CBL | P22681 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25360442 | 0.89 | CBLB (0.61) | CBLBCBL | |
| SCHEMBL25358972 | 0.89 | CBLB (0.62) | CBLBCBL | |
| SCHEMBL31115405 | 0.86 | CBLB (0.60) | CBLB | |
| SCHEMBL25360512 | 0.86 | CBLB (0.60) | CBLB | |
| SCHEMBL31578380 | 0.85 | CBLB (0.66) | CBLBCBL | |
| SCHEMBL30625466 | 0.83 | CBLB (0.52) | CBLB | |
| SCHEMBL30625557 | 0.83 | CBLB (0.52) | CBLB | |
| SCHEMBL30625569 | 0.83 | CBLB (0.52) | CBLB | |
| SCHEMBL30625489 | 0.83 | CBLB (0.59) | CBLBCBL | |
| SCHEMBL30625610 | 0.83 | CBLB (0.52) | CBLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163047-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE, LTD. (KY) | 2025-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163047-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | NFATC1, GZMB, IFNG | CBLB 2362/4885CBL 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.